A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

Background This trial evaluated the safety, tolerability and maximum tolerated dose (MTD) of afatinib, a novel ErbB Family Blocker. Methods In this open-label, dose-escalation Phase I study, afatinib was administered continuously, orally, once-daily for 28 days to patients with advanced or metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Michael S., Mendelson, David S., Gross, Mitchell, Uttenreuther-Fischer, Martina, Ould-Kaci, Mahmoud, Zhao, Yihua, Stopfer, Peter, Agus, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589633/
https://www.ncbi.nlm.nih.gov/pubmed/23242861
http://dx.doi.org/10.1007/s10637-012-9904-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589633/
https://www.ncbi.nlm.nih.gov/pubmed/23242861
http://dx.doi.org/10.1007/s10637-012-9904-9

Ejemplares similares